Agenus, Inc. (AGEN)
7.67
+0.13
(+1.72%)
USD |
NASDAQ |
Oct 09, 16:00
7.655
-0.02
(-0.20%)
Pre-Market: 20:00
Agenus Cash from Operations (Quarterly) : -31.20M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.20M |
| March 31, 2026 | -35.95M |
| December 31, 2025 | -16.62M |
| September 30, 2025 | -14.74M |
| June 30, 2025 | -20.22M |
| March 31, 2025 | -25.62M |
| December 31, 2024 | -28.65M |
| September 30, 2024 | -53.29M |
| June 30, 2024 | -38.18M |
| March 31, 2024 | -38.19M |
| December 31, 2023 | -40.40M |
| September 30, 2023 | -65.23M |
| June 30, 2023 | -60.04M |
| March 31, 2023 | -58.53M |
| December 31, 2022 | -47.34M |
| September 30, 2022 | -32.19M |
| June 30, 2022 | -43.45M |
| March 31, 2022 | -52.39M |
| December 31, 2021 | -22.93M |
| September 30, 2021 | 131.37M |
| June 30, 2021 | -55.56M |
| March 31, 2021 | -42.74M |
| December 31, 2020 | -35.59M |
| September 30, 2020 | -31.63M |
| June 30, 2020 | -37.38M |
| Date | Value |
|---|---|
| March 31, 2020 | -34.50M |
| December 31, 2019 | -31.78M |
| September 30, 2019 | -27.78M |
| June 30, 2019 | -35.70M |
| March 31, 2019 | 76.59M |
| December 31, 2018 | -35.81M |
| September 30, 2018 | -24.50M |
| June 30, 2018 | -30.53M |
| March 31, 2018 | -40.25M |
| December 31, 2017 | -25.87M |
| September 30, 2017 | -26.15M |
| June 30, 2017 | -27.38M |
| March 31, 2017 | -14.83M |
| December 31, 2016 | -16.12M |
| September 30, 2016 | -23.82M |
| June 30, 2016 | -18.49M |
| March 31, 2016 | -21.53M |
| December 31, 2015 | -19.59M |
| September 30, 2015 | -18.01M |
| June 30, 2015 | -12.87M |
| March 31, 2015 | 3.295M |
| December 31, 2014 | -10.51M |
| September 30, 2014 | -8.106M |
| June 30, 2014 | -9.496M |
| March 31, 2014 | -10.12M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 240.89M |
| Novavax, Inc. | -72.81M |
| AVITA Medical, Inc. | -3.630M |
| Iovance Biotherapeutics, Inc. | -60.84M |
| Amgen, Inc. | 4.002B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 0.267M |
| Cash from Financing (Quarterly) | 14.68M |
| Free Cash Flow | -98.50M |
| Free Cash Flow Per Share (Quarterly) | -0.7547 |
| Free Cash Flow to Equity (Quarterly) | -16.91M |
| Free Cash Flow to Firm (Quarterly) | -15.84M |
| Free Cash Flow Yield | -34.76% |